Mabpharm Valuation
Is 2181 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Sales vs. similares
Price-To-Sales vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of 2181 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: Datos insuficientes para calcular el valor razonable de 2181 para el análisis de valoración.
Muy por debajo del valor justo: Datos insuficientes para calcular el valor razonable de 2181 para el análisis de valoración.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2181?
Other financial metrics that can be useful for relative valuation.
| What is 2181's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥1.75b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 21.4x |
| Enterprise Value/EBITDA | -11.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2181's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.4x | ||
1672 Ascletis Pharma | 22.3x | -20.1% | HK$1.4b |
2487 Cutia Therapeutics | 14.4x | 39.2% | HK$2.1b |
1061 Essex Bio-Technology | 0.8x | 16.5% | HK$1.3b |
2315 Biocytogen Pharmaceuticals (Beijing) | 4.1x | 21.3% | HK$3.1b |
2181 Mabpharm | 20.1x | n/a | HK$1.9b |
Price-To-Sales vs. similares: 2181 es caro según su Ratio Price-To-Sales (15x) en comparación con la media de sus homólogos (14.8x).
Price to Earnings Ratio vs Industry
How does 2181's PE Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Sales vs. Industria: 2181 es caro en función de su Ratio Price-To-Sales (25x) en comparación con la media del sector Hong Kong Biotechs (12x).
Price to Sales Ratio vs Fair Ratio
What is 2181's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 20.1x |
| Fair PS Ratio | n/a |
PM vs. Ratio Justo: Datos insuficientes para calcular 2181's Price-To-Sales Fair Ratio para el análisis de valoración.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Pronóstico de los analistas: Datos insuficientes para mostrar el pronóstico de precios.